文献速递白血病淋巴瘤

维奈克拉联合多药化疗治疗15例复发难治早期前体T淋巴细胞白血病患者的临床疗效与安全性

[Clinical efficacy and safety of venetoclax combined with multidrug chemotherapy in the treatment of 15 patients with relapsed or refractory early T-cell precursor acute lymphoblastic leukemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2023-01-01

回顾性分析2018年12月至2022年2月苏州大学附属第一医院15例复发难治早期前体T淋巴细胞白血病患者,接受维奈克拉联合多药化疗,第21天总有效率66.7%,完全缓解率60.0%,12个月总生存率60.0%,中位总生存17.7个月,3级及以上血液学不良反应14例,无神经系统不良反应及肿瘤溶解综合征。

要点

  • 维奈克拉联合多药化疗治疗R/R ETP-ALL第21天完全缓解率60.0%(9/15),总有效率66.7%。
  • 全部患者12个月总生存率60.0%,中位总生存17.7个月;完全缓解患者12个月无病生存率60.0%。
  • 14例(93.3%)发生3级及以上血液学不良反应,均可控,无致死性大出血及3级及以上脏器不良反应。

核心结论

  • 维奈克拉联合多药化疗治疗复发难治早期前体T淋巴细胞白血病疗效值得肯定,治疗相关不良反应可耐受。

研究设计与样本

  • 回顾性分析2018年12月至2022年2月在苏州大学附属第一医院住院治疗的15例复发难治早期前体T淋巴细胞白血病患者。
  • 再诱导治疗以维奈克拉为基础联合多药化疗:8例联合去甲基化药物,4例同时联合去甲基化药物和HAAG方案,2例同时联合去甲基化药物和CAG预激方案,1例联合克拉屈滨。
  • 维奈克拉用法为100 mg第1天,200 mg第2天,400 mg第3~28天,口服;联合唑类抗真菌药物时减量至100 mg/d。

主要发现

  • 15例患者中男10例、女5例,中位年龄35(12~42)岁;难治4例,复发11例。
  • 用药第21天完全缓解率为60.0%(9/15),完全缓解伴血液学不完全恢复率为6.7%(1/15),总有效率为66.7%。
  • 所有患者12个月总生存率为60.0%,中位总生存时间为17.7个月。
  • 全部完全缓解患者12个月无病生存率为60.0%,中位无病生存时间未达到。
  • 14例(93.3%)患者发生3级及以上血液学不良反应,经治疗后造血功能恢复且无致死性大出血发生;无患者出现神经系统不良反应及肿瘤溶解综合征,无3级及以上脏器不良反应发生。

临床怎么用

  • 原文结论认为维奈克拉联合多药化疗可能是复发难治早期前体T淋巴细胞白血病患者安全且有前景的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the efficacy and safety of Venetoclax combined with multidrug chemotherapy in patients with relapsed or refractory early T-cell precursor acute lymphoblastic leukemia (R/R ETP-ALL) . Methods: This study retrospectively analyzed 15 patients with R/R ETP-ALL who received Venetoclax combined with multidrug chemotherapy from December 2018 to February 2022. Among them, eight cases were combined with demethylated drugs, four cases were combined with demethylated drugs and HAAG chemotherapy regimen, two cases were combined with demethylated drugs and CAG regimen, and one case was combined with Cladribine. Specific usage and dosage of Venetoclax: 100 mg on day 1, 200 mg on day 2, 400 mg on day 3-28, orally; when combined with azole antifungal drugs, dosage was reduced to 100 mg/d. Results: Fifteen patients (10 males and 5 females) with R/R ETP-ALL were treated with Venetoclax and multidrug chemotherapy with a median age of 35 (12-42) years old. Of 4 refractory and 11 relapsed patients, the efficacy was evaluated on the 21th day following combined chemotherapy: the overall response rate, the complete response (CR) rate, and the CR with incomplete hematological recovery (CRi) rate were 67.7% (10/15), 60.0% (9/15), and 6.7% (1/15), respectively. For the overall study population, the 12-month overall survival (OS) rate was 60.0%, and the median OS was 17.7 months. The disease-free survival (DFS) rate of all CR patients at 12 months was 60.0%, and the median DFS did not reach. About 14 patients had Ⅲ-Ⅳ hematological toxicity, but these adverse reactions were all controllable. No adverse reaction in the nervous system and tumor lysis syndrome occurred in this study, and no adverse reaction of organs above grade Ⅲ occurred. Conclusion: Venetoclax combined with multidrug chemotherapy may be a safe and promising treatment option for patients with R/R ETP-ALL. 目的: 探讨维奈克拉(Venetoclax,Ven)联合多药化疗治疗复发难治早期前体T淋巴细胞白血病(R/R ETP-ALL)患者的疗效及安全性。 方法: 回顾性分析2018年12月至2022年2月在苏州大学附属第一医院住院治疗的15例R/R ETP-ALL患者的临床资料。再诱导治疗以Ven为基础联合多药化疗,其中8例联合去甲基化药物,4例同时联合去甲基化药物和HAAG方案,2例同时联合去甲基化药物和CAG预激方案,1例联合克拉屈滨。Ven用法为100 mg第1天,200 mg第2天,400 mg第3~28天,口服;联合唑类抗真菌药物时减量至100 mg/d。 结果: 15例R/R ETP-ALL患者中,男10例,女5例,中位年龄35(12~42)岁。难治4例,复发11例。用药第21天疗效:完全缓解(CR)率为60.0%(9/15),CR伴血液学不完全恢复(CRi)率为6.7%(1/15),总有效率(ORR)为66.7%。所有患者12个月总生存(OS)率为60.0%,中位OS时间为17.7个月;全部CR患者12个月无病生存(DFS)率为60.0%,中位DFS时间未达到。14例(93.3%)患者发生了3级及以上血液学不良反应,所有患者经治疗后造血功能恢复且无致死性大出血发生;无患者出现神经系统不良反应及肿瘤溶解综合征,同时无3级及以上脏器不良反应发生。 结论: Ven联合多药化疗治疗R/R ETP-ALL疗效值得肯定,治疗相关不良反应可耐受。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Kong JY, Zong LH, Pu Y, et al. [Clinical efficacy and safety of venetoclax combined with multidrug chemotherapy in the treatment of 15 patients with relapsed or refractory early T-cell precursor acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 37803838. doi:10.3760/cma.j.issn.0253-2727.2023.08.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。